Soho House CEO Andrew Carnie confirmed the members-only hospitality group has pivoted its wellness programming from traditional spa services to IV infusion therapy and biohacking protocols, timing the announcement with the completion of a $2.7 billion take-private transaction. The shift arrives as the company exits public markets and installs actor-investor Ashton Kutcher on its board, signaling a fundamental repositioning of what wellness means inside the club's 42 global houses.

Carnie told The Guardian the move reflects observed member behavior over the past 18 months. Two-martini evenings have given way to requests for vitamin drips, cold-plunge protocols, and performance biomarkers. The company now offers IV infusion services in select houses and is testing partnerships with biohacking vendors for metabolic and longevity programming. Exact pricing and rollout timelines remain undisclosed, but the CEO framed the wellness pivot as permanent rather than experimental.

The strategic shift matters because Soho House owns one of the narrowest addressable audiences in hospitality—roughly 230,000 members across creative and media industries who pay between $1,800 and $4,800 annually depending on location and tier. This cohort skews younger, wealthier, and more health-conscious than the country-club demographic that historically drove wellness revenue in private clubs. If Soho House can monetize longevity services at scale without alienating its core identity, it establishes a template for other membership hospitality groups facing the same generational recalibration. The company's ability to test and iterate behind closed doors, now that it has exited public markets, removes quarterly-earnings pressure that constrained similar pivots at competitors like Equinox or Core Club.

Kutcher's board appointment is not ornamental. His venture firm, Sound Ventures, holds positions in longevity-focused companies including Levels (continuous glucose monitoring) and Inside Tracker (biomarker testing). His presence suggests Soho House may vertically integrate or white-label biohacking technology rather than relying on third-party vendor partnerships. The company already operates food-and-beverage programs in-house; extending that control to wellness services would allow margin capture and data ownership that partnership models forfeit. The $2.7 billion take-private valuation, led by a consortium including founder Nick Jones and existing investor Ron Burkle, gives management room to invest in infrastructure without immediate return-on-investment scrutiny.

Operators should watch for three signals over the next six to nine months: first, whether Soho House expands IV and biohacking services beyond pilot locations to full systemwide rollout; second, whether membership growth accelerates or decelerates as the wellness pivot becomes visible (the company has not disclosed member churn data since going private); third, whether legacy luxury clubs—Norwood, Metropolitan Club, University Club—begin testing similar longevity programming to defend against member migration. Heritage hospitality groups have historically moved slowly on wellness innovation, but a visible success at Soho House could compress decision cycles.

The company's next earnings will be private, but wellness revenue as a percentage of total ancillary income will be the number that determines whether this pivot was positioning or performance.